The Drug Report

Drug policy in America is at a critical inflection point. Following a period dominated by extreme harm reduction approaches, we're witnessing a significant shift back toward accountability-based treatment models. This transformation comes as cities like San Francisco and states like Oregon roll back failed experiments that provided tools for addiction without addressing its root causes.Dr. Kevin Sabet joins us fresh from United Nations meetings in Vienna, where American representation was noticeably diminished – a symptom of the current administration's still-developing drug policy strategy. Together, we analyze Dr. Nora Volkow's recent Stat News interview, where the longtime NIDA Director expressed skepticism about universalizing 12-step approaches despite compelling research supporting their effectiveness. As Sabet points out, studies from leading institutions demonstrate that 12-step programs often outperform traditional psychotherapy while lowering healthcare costs.The encouraging decline in opioid overdose deaths presents a complex puzzle we attempt to unravel. Is it increased naloxone availability? Greater public awareness of fentanyl dangers? The tragic reality that many vulnerable users have already died? The answer likely combines these factors, highlighting why comprehensive approaches that blend harm reduction tools with accountability-focused recovery pathways remain essential. As America recalibrates its drug policy strategy, this conversation offers crucial context for understanding what works, what doesn't, and why the pendulum is swinging back toward treatment models that emphasize personal responsibility alongside compassionate care.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

The fentanyl crisis represents one of America's most pressing public health emergencies, one that has affected countless families and communities across the country. In this engaging episode with Dr. Robert Marbut, we explore the alarming statistics surrounding fentanyl's impact, which has become a leading cause of death, eclipsing even the toll from warfare. Dr. Marbut, a distinguished expert on homelessness and addiction, unpacks the connection between structural issues like mental health and substance use, shedding light on the intricacies of these intertwined crises. Throughout our conversation, we delve into how societal factors such as loneliness and consumer culture contribute to higher rates of fentanyl use and addiction. Dr. Marbut emphasizes the importance of reclaiming family dynamics in the fight against addiction, noting that two-thirds of the experts pointed to the need for strengthening family bonds as a crucial step toward alleviating these issues. Listeners gain unique insights into the making of the documentary “Fentanyl: Death Incorporated,” which aims to bring these discussions to a broader audience. Dr. Marbutt shares behind-the-scenes anecdotes that underscore the power of storytelling as a means to foster empathy and inspire action. This episode isn't just about statistics; it's an urgent call to consider how we can collectively change our response to the crisis. By fostering a culture of connection, understanding, and accountability, we stand a better chance against this existential threat. Join us in this important discussion and explore how you can be part of the solution. Subscribe for more insightful discussions on drug policy, community action, and strategies to tackle addiction head-on. Don't forget to leave a review and share this episode with someone who can help raise awareness.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

High THC cannabis products are under intense scrutiny, and with good reason. Kevin Sabet, CEO of SAM Smart Approaches to Marijuana, joins us to dissect the cannabis industry's parallels with big tobacco, especially concerning unproven health claims and the relentless drive for profit. We examine a noteworthy New York Times article and question whether New York's $1 billion in cannabis sales is worth the potential cost to public health. Our discussion focuses on prioritizing health over profit, learning from the tobacco industry's past mistakes, and the crucial role of effective regulation in safeguarding public health. Our global audience is at the heart of what we do, and your support is invaluable. We are grateful to Kevin for his insights and extend our appreciation to listeners across dozens of countries and countless cities. We're excited to continue bringing you the most pressing news and updates, and we encourage you to share our podcast with others who care about the future of drug policy and public health. If our conversations resonate with you, please leave us a five-star review and share your thoughts as we strive to spark change and meaningful dialogue.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Can relentless advocacy truly shape the future of marijuana legislation? Join us on the Drug Report podcast as we explore the recent triumph in New Hampshire, where the unwavering efforts of advocates have led Governor Kelly Ayotte to promise a veto on any future marijuana legalization attempts. This victory shines a light on the power of persistence in the ever-evolving landscape of drug policy. As we navigate through these pivotal changes, we're also dissecting the challenges faced by the marijuana industry in New York, revealing how initial promises of social equity have not been fulfilled, leaving many equity applicants in financial distress. Kevin Sabet's op-ed adds a critical perspective to our discussion, emphasizing the widening gap between wealthy investors and disenfranchised communities.Our conversation takes a crucial turn as we tackle issues surrounding medical marijuana prescriptions, drawing comparisons to the opioid crisis of the 1990s. How can we ensure patient safety when a small group of doctors dominates the recommendation landscape? We're also looking at the ongoing efforts in Florida to legalize marijuana and the strategic legislative initiatives being considered by the new Congress. Randy's resolution serves as a cornerstone in raising awareness about the risks of high-potency THC, reflecting a broader strategic approach to drug policy reform and patient protection.Federal marijuana legalization remains a hot topic, with the complexities of state and federal enforcement at the forefront. We address the urgent need for Congress to empower the DOJ in regulating marijuana sales near schools, while also examining the emerging debate around Delta 8, especially as companies like DoorDash enter the market. The unexpected halt in the marijuana rescheduling process due to an industry-filed motion has opened the door for broader scrutiny and discussion. President Trump's ambiguous remarks about the Safe Banking Act add another layer of uncertainty, as we acknowledge the collaborative efforts of advocates striving to navigate these challenging waters. Join us as we break down these pressing issues and stay informed on the latest developments.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Could the defeat of Florida's marijuana legalization measure signal a turning tide in drug policy across America? Despite an avalanche of financial backing and celebrity endorsements, Florida's initiative fell short, leaving many to question the power dynamics at play. Join us as we unpack the surprising outcome, delving into the influential role of grassroots campaigns and bipartisan voices, such as the powerful advocacy from former congresswoman Donna Shalala. Discover how "Don't Let Florida Go to Pot" captured the public's attention and vote, challenging the narrative that financial clout guarantees success in the ballot box.Explore the broader shift in drug policy attitudes nationwide, as marijuana legalization efforts face unexpected setbacks in states like North and South Dakota. These defeats highlight the power of community coalitions and parental advocacy in steering public opinion. With concerns over youth usage and black market proliferation, the narrative that marijuana legalization is an unstoppable force is being rewritten. Celebrate these grassroots victories as we spotlight the relentless efforts of local communities standing up to well-funded legalization campaigns.Look to Massachusetts, where the conversation takes a fascinating turn towards psychedelic legalization in progressive hubs like Boston, Cambridge, and Somerville. Uncover the state's storied connection to psychedelics and the surprising voting patterns that emerged. Meanwhile, in Colorado Springs, a significant ban on marijuana sales underscores a commitment to public health priorities. We acknowledge the unwavering dedication of organizations like SAM and the Foundation for Drug Policy Solutions, whose work has been instrumental in these recent victories, marking a pivotal moment in the fight for sensible drug policies.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Discover the complexities of today's drug policy landscape with insights from around the globe. We promise an enlightening journey as Kevin Sabat and I unpack the highlights from the recent Lisbon Addictions Conference. We bring you the latest updates and debates on harm reduction versus legalization, spotlighting data-driven discussions from regions like Oregon and British Columbia. As we shift focus to the United States, uncover the stories behind various drug policy ballot measures, including marijuana legalization efforts in Florida and the Dakotas. The challenges New York faces in its legalization journey serve as a cautionary tale, and we even touch on an intriguing psychedelics measure in Massachusetts, hinting at the evolving dynamics in drug policy.In a special segment, Kevin joins me to highlight the importance of staying informed through resources like newsletters from learnaboutsamorg and thedrugreportorg. We emphasize the value of evidence-based policies and encourage robust discussions among our listeners. Make sure to engage with us by subscribing to these newsletters for the latest updates and leave a review to help amplify the conversation. Tune in for a comprehensive understanding of the forces shaping the future of drug policy around the world.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Is federal marijuana legalization truly a win for Black men, or are there hidden pitfalls? Join us as we take a hard look at Vice President Kamala Harris's proposal, focusing on its goal to dismantle systemic barriers and whether it achieves this when it poses new public health risks. With insightful commentary from Will Jones of SAM, we unravel the intricate dynamics between promising business opportunities and the risks of corporate exploitation in the marijuana industry. By drawing parallels with historical public health challenges like the tobacco industry's impact, we critically question whether this federal move could inadvertently harm the communities it seeks to empower.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Can marijuana regulation backfire on public health? Join us on the Drug Report podcast as we celebrate International Recovery Day and tackle this provocative question with insights from experts like Michael Botticelli and John Kelly. We'll share highlights from a global webinar focused on the mechanisms and societal support necessary for successful recovery. We'll also respond to Robert Gebeloff's Washington Post column advocating for federal marijuana regulation, raising concerns about big tobacco's potential entry into the marijuana market and the resulting public health issues. Plus, you'll hear a detailed recount of the recent debate on Florida's Amendment 3 for recreational marijuana legalization, shedding light on the ongoing complexities in drug policy reform.Are veterans being misled about marijuana's effects on PTSD? In a crucial segment of this episode, Kevin Sabet and I dismantle the misinformation spreading within veteran communities. Drawing on recent studies, including research from Yale University, we reveal that marijuana may actually worsen PTSD symptoms, contradicting popular belief. We underscore the importance of distributing accurate information to better support our veterans and encourage our listeners to help by leaving a five-star rating and writing a review. Gain valuable insights and join the conversation on drug policy and recovery by tuning in to this thought-provoking and informative episode.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Can the FDA really pull THC-infused edibles off the shelves? We'll take you inside a gripping congressional hearing where FDA Deputy Commissioner for Human Foods, James Jones, found himself in the hot seat, interrogated by Congresswoman Kathy McMorris-Rogers. Unravel the complexities of the Federal Food, Drug, and Cosmetic Act and understand the real-world implications of the Blumenauer Amendment, which ties the FDA's hands when it comes to medical marijuana dispensaries that also sell recreational products.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Can a balanced approach to harm reduction and recovery really save lives? Join us in a thought-provoking conversation with Tom Wolf, a member of the Recovery community from San Francisco, offering a raw and unfiltered critique of today's drug policies. We scrutinize Vancouver's harm reduction model and its alarming overdose death rates, while Tom passionately argues for recovery-focused solutions in the face of new proposals advocating "safe" drug-use spaces and other radical drug provisions. This episode sheds light on the crucial need to integrate more sensible harm reduction interventions with prevention, treatment, and recovery initiatives for a more humane and effective drug policy.Dive deep into the broader debate on drug policy strategies as we question advocates' desire to legalize all drugs, scrutinize the opioid crisis, and expose the cultural influence of big corporations on advocacy. With Tom's powerful insights, we explore how recovery voices must lead the way in policymaking. Listen as we highlight real-life advocacy successes from San Francisco and discuss the vital role of individuals in recovery in shaping policies that truly address addiction. This episode is a comprehensive examination of the pressing issues in drug policy, offering a blueprint for a balanced and recovery-centric approach.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Can marijuana use really be costing businesses millions? In this episode of the Drug Report Podcast, we unpack a revealing study from the American Journal of Preventative Medicine that draws a stark connection between cannabis use disorder and rising workplace absenteeism. From the financial strain on employers to the ripple effects on the economy, we analyze the true cost of marijuana in the workplace. We also bring to light alarming data from Quest Diagnostics, showing a surge in marijuana positivity rates, particularly following workplace accidents. Join us as we discuss the crucial need for robust drug prevention and treatment policies to sustain a safe and efficient work environment.But that's not all—we also expose a worrying trend within Pennsylvania's medical marijuana program. Through a gripping story from a Pennsylvania series, we uncover how doctors with checkered pasts, including drug dealing and revoked medical licenses, are still issuing medical marijuana cards. This revelation prompts us to question the integrity of medical marijuana programs and the potential for similar issues nationwide. We emphasize the vital role of media in shining a light on such misconduct and discuss the broader implications for the medical community and public trust. Tune in for a comprehensive look into these critical issues affecting workplace dynamics and public health.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

This episode of the Drug Report podcast unpacks the FDA's recent decision to reject Lykos' psilocybin product intended for treating PTSD, a move that has sparked fierce debate. We also delve into the significant fallout for Lykos, from massive layoffs and leadership upheavals to the company's uncertain future. Plus, the tragic case of Matthew Perry is intertwined with broader concerns about the safety and efficacy of psychedelic treatments.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Can marijuana legalization really dismantle our overcrowded prisons? Find out in today's episode as we unravel the myths and misconceptions about marijuana possession and imprisonment. We begin by examining the widely held belief that legalizing marijuana will significantly reduce prison populations. Using President Biden's historic federal pardons as a case study, we expose the reality: no one was serving federal prison time for simple marijuana possession and the impact of these pardons was far less extensive than most believe.In the second half, our focus shifts to the real data behind marijuana-related imprisonment in states like Michigan and Florida, revealing that very few people are incarcerated solely for minor marijuana offenses. We also bring to light the health risks associated with regular marijuana use, with a significant study from the University of Southern California showing a three to five-fold increased risk of developing head and neck cancers among daily users. As we draw parallels to the historical impact of tobacco, we stress the importance of informed public awareness to prevent a similar health crisis. Stay informed, stay engaged, and thank you for your continued support.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

What if the very strategies intended to reduce harm from drug use are actually endangering the very people they aim to protect? This episode of the Drug Report promises to tackle the complexities and controversies surrounding research into harm reduction in drug policy. With significant federal funding now backing harm reduction research, we stress the critical importance of reputable science in shaping effective policies. Hear our nuanced critique on the growing influence of drug normalization in policy-making, through revealing case studies like the Greater Harlem Coalition's experience with pro-drug Yale researchers.But that's not all. We dive into the murky waters of ethical concerns surrounding drug research, spotlighting the scandal involving Lykos (formerly MAPS) and its contentious clinical trials for psychedelic drugs. The Wall Street Journal's reports on unreported suicidal ideation among trial subjects raise alarming questions about participant safety and research ethics, echoing historical parallels with the tobacco industry. Finally, don't miss out on our exciting announcement about the TDR newsletter, brimming with insightful articles and a compelling editorial piece. Your feedback is invaluable to us, and we hope you find this episode as thought-provoking as we do.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Join us as we take you through the gripping details of Philip Morris' latest move to build a "Zyn" nicotine pouch factory in Aurora, Colorado—their first U.S. factory in half a century. This episode kicks off with a bold discussion on my recent op-ed critiquing the economic incentives granted by the Aurora City Council and the uncritical media coverage of this development. We expose the alarming health risks tied to these products, especially as they skyrocket in popularity among young people.We'll also explore the dark history of Philip Morris, delving into their targeted marketing that has ravaged vulnerable communities—youth and people of color, in particular. From the aggressive advertising strategies to the public health crisis wrought by tobacco, this episode sheds light on the devastating consequences of these addictive products. Tune in to understand the ongoing battle against big tobacco and why staying informed about the repercussions of nicotine products is more crucial than ever.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

We've uncovered a troubling trend: marijuana use is on the rise among pregnant mothers, posing severe health risks to both them and their babies. With evidence from a recent study by Kaiser, we discuss the alarming increase in gestational hypertension, preeclampsia, lower birth weights, preterm birth, and higher neonatal intensive care admissions linked to marijuana use during pregnancy. Even more concerning, many dispensaries are recommending marijuana to pregnant women—a dangerous echo of past marketing tactics by the alcohol industry. We urgently call for stringent regulations and public health warnings to protect vulnerable mothers and their unborn children from these significant risks.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Can the profit motive in free markets lead to disastrous outcomes when it comes to addictive substances like marijuana? We explore this vital question with Charles Lehman from the Manhattan Institute, who brings a compelling analysis of the economic and societal impacts of marijuana legalization. Charles discusses the tension between individual rights and community well-being, emphasizing how addiction can significantly distort rational self-interest. We also shine a light on the often-overlooked societal costs, such as increased emergency services and workplace accidents, that accompany marijuana legalization. In our conversation, we unravel the complexities of addiction and the predictable failures of rationality it involves, using the opioid crisis as a striking example. We delve into Mark Kleiman's innovative ideas on marijuana regulation and the challenges of prohibition versus legalization. Political motivations behind marijuana pardons and changing public sentiments towards legal cannabis are also dissected. Tune in for personal reflections on marijuana use and insights from those in recovery, shaping a broader understanding of drug policy and addiction.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Unlock the secrets behind the federal drug policies that shape our nation's approach to marijuana regulation. Join us as we sit down with Jordan Davidson, head of government affairs at Smart Approaches to Marijuana (SAM), to discuss their strategic initiatives against the federal rescheduling of marijuana. Learn how SAM has effectively rallied influential lawmakers like Senator Mitt Romney to lead the charge on congressional letters and appropriations amendments, ensuring that rescheduling efforts are grounded in rigorous scientific analysis. Discover the pivotal role of report language in guiding agency actions and the impact of coordinated opposition from 18 state attorneys general.Get an insider's perspective on the legislative maneuvers that have successfully blocked the legalization of recreational marijuana in Washington DC, including the powerful Andy Harris rider and a decade-long DOJ restriction on state-legal medical marijuana programs. We discuss the significant new exception to enforce the Drug-Free School Zones Act, emphasizing public health and safety backed by compelling data from a University of Michigan survey. Finally, we explore the growing awareness reflected in recent agricultural and FDA appropriations bills, showcasing our collective effort to prioritize the well-being of our communities. Don't miss this comprehensive discussion on SAM's federal drug policy priorities and the critical measures taken to safeguard public health.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Excerpt from Luke's interview on WMAL DMV Talkshow: Could the commercialization of marijuana be putting our youth at risk? Join us in our latest episode as we sit down with Luke Niferatos, the Executive Vice President of Smart Approaches to Marijuana (SAM), to unpack the alarming rise in daily marijuana use among teenagers and young adults. Luke sheds light on the health risks linked to high-potency marijuana, such as psychosis, depression, and academic decline, and how these concerns have been overlooked by states hurrying to legalize recreational cannabis. This conversation is a must-listen for anyone concerned about the well-being of our younger generations and the unforeseen public health consequences of marijuana legalization.Luke also explores the intricate landscape of marijuana legalization policies, including potential rollbacks and societal impacts witnessed in places like Thailand and Colorado. We expose the misuse of social justice arguments by the marijuana industry and argue for genuine reforms such as decriminalizing low-level possession and expunging records. Using Denver as a case study, we discuss the glaring disparities in marijuana shop locations and ownership within minority communities, while also highlighting recent legislative changes in Maryland. Tune in to understand why it's crucial for policymakers to rely on scientific research, particularly concerning the mental health effects of today's high-potency marijuana.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Is the safety of legal marijuana a myth? Join me, Luke Nioratos, on this week's TDR Podcast as we expose shocking truths revealed by the LA Times in their eye-opening series, "California's Problem with Contaminated Weed." Legal cannabis was supposed to offer a safer alternative, but our exploration uncovers a disturbing reality—pesticide-tainted products that have been knowingly left on the shelves by California regulators. Discover how these dangerous cultivation practices not only pose significant health risks to consumers but also have severe environmental impacts, threatening wildlife and ecosystems.We'll broaden our investigation to other states like Oregon and Colorado, where similar issues plague the legal marijuana industry. In Oregon, a 2019 review by the state's Secretary of State revealed alarming deficiencies in product testing and regulation, further emphasizing the urgent need for reform. This episode is a call to action for stricter oversight and accountability to protect both consumers and the environment. Don't miss this critical conversation that pulls back the curtain on the dark side of legal marijuana and the dire need for systemic change.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Join us as we dissect Vermont's legislative decision to establish an injection site in Burlington, despite Governor Phil Scott's veto. We'll scrutinize the mixed results from British Columbia and other regions to question the efficacy and safety of these facilities. Then, let's debunk the myths around youth marijuana use trends from the Colorado Healthy Kids Survey. We'll expose how changes in data collection methods have created misleading results, urging us to reconsider if our resources could be better spent on prevention, treatment, and recovery initiatives.This episode also dives into the ongoing efforts surrounding marijuana rescheduling, emphasizing the importance of public involvement in shaping drug policy. Stay informed and engaged by visiting learnaboutsam.org and thedrugreport.org for more details and twice-weekly updates. Don't miss this essential conversation that cuts through the noise to propose more effective approaches to today's drug policy challenges.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Join us for this audio version of last week's zoom webinar on rescheduling,  a deep dive into the intricate world of drug scheduling and addiction with our esteemed guests: Kevin Sabet, President and CEO of SAM, CADCA  policy consultant Sue Thau, and Dr. Russ Kamer. We kick things off by breaking down the history and impact of the 1970 Controlled Substances Act, using relatable analogies to dispel common misconceptions about drug classification. This sets the stage for a compelling discussion on public perception, medical use, and the complexities of drug policy reform.Get ready for an eye-opening analysis of President Biden's efforts to reschedule marijuana. Starting with a review by the Department of Health and Human Services in October 2022, the process reached an unexpected climax in August 2023. We dissect the irregularities of potentially moving marijuana to Schedule 3 and consider the implications for tax obligations, FDA oversight, and research opportunities. Our panelists bring their unique perspectives to unravel the complexities and uncertainties surrounding this significant policy shift.Public safety and health implications of rising marijuana use are our final focus. Learn how marijuana's prevalence compares to alcohol and why it's crucial to address misconceptions about its safety. We delve into the challenges of measuring marijuana impairment and emphasize the urgent need for reliable testing methods. With insights from Kevin Sabet, Sue Thau, and Dr. Russ Kamer, we encourage you to engage thoughtfully in the regulatory process and consider the broader implications of these monumental changes in drug policy. Tune in and stay informed!Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Join us for an eye-opening discussion with Jordan Davidson as he unpacks the latest legislative movements on Capitol Hill. From the inclusion of a Delta-8-THC ban in critical bills to the intricate lobbying efforts that shape these laws, Jordan brings firsthand insights that you won't want to miss. This episode is packed with updates on the Farm Bill, the agriculture appropriations bill, and the powerful forces working behind the scenes.Tune in to understand how public health advocates are making strides in a space traditionally dominated by industry lobbyists. Jordan and I also discuss the potential impacts of the Safe Banking Act and the Harris rider amendment, providing you with a comprehensive look at what's next for marijuana and hemp regulation. Whether you're a policy wonk or just curious about how these legislative processes unfold, this episode promises to enlighten and inform.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

What happens when a man transforms his life from the depths of addiction and homelessness to leading a top recovery program? Join us as Paul Scudo, CEO of STEP Denver, opens up about his harrowing yet inspiring journey. Paul shares an intimate look at his battle with addiction, the support that pulled him through, and his remarkable rise from volunteer to CEO, blending his lived experiences with business expertise to revolutionize addiction recovery.Discover the unique approach of STEP Denver, a men's residential recovery program that's breaking the mold. This isn't your typical clinical treatment facility; instead, STEP emphasizes real-world responsibilities like holding a full-time job, saving money, and learning financial literacy. Paul highlights the power of community and accountability in their program, which has led to impressive success rates and life-changing results for many men.We also dive into the broader societal issues of addiction and homelessness, examining the evolving public policies and their impact. Paul offers a critical perspective on the importance of personal accountability amidst these challenges and discusses STEP Denver's no-government-funding stance. This conversation not only sheds light on the transformative work being done at STEP but also contemplates the future of addiction recovery and public health policies. Tune in to understand the profound impact one individual can make and the importance of fostering independence in recovery.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Why did an FDA panel recently decisively reject MDMA for medical use despite some supportive scientific studies? Join us on the TDR podcast as we grapple with this critical and controversial topic alongside our distinguished guest, Kevin Sabet. In this episode, we unpack the intricate history and ambitions of MAPS, the organization led by Rick Doblin, which transformed into the for-profit Lycos Therapeutics. Kevin offers his expertise on the mixed results from rigorous studies submitted to the FDA and the factors behind the panel's overwhelming vote against MDMA for treating PTSD. This discussion sheds light on the broader implications for psychedelic therapies and FDA regulations.We also delve into the media frenzy and the optimistic anticipation within the psychedelics advocacy community leading up to the panel's decision. Despite the buzz and support from certain quarters, the committee's vote of 10 to 1 against MDMA underscores the complexities and risks associated with approving psychedelics for medical use. Get ready for a comprehensive analysis of this pivotal decision and its potential impact on the future landscape of PTSD treatments. Tune in for valuable insights on what lies ahead for MDMA in therapeutic settings and the FDA's ultimate stance.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

What if the rise in marijuana use mirrors the patterns of cigarette smoking more than alcohol consumption? Join us as we sit down with Dr. Jonathan Caulkins, a preeminent expert on drug policy, to explore his groundbreaking research on cannabis use trends from 1979 to 2022. Dr. Calkins unveils a startling shift towards high-intensity use, revealing that daily or near-daily users now dominate the market and consume significantly higher amounts of THC. This transformation carries enormous implications, particularly as increased availability and societal normalization continue to reshape the marijuana landscape.We further discuss the growing prevalence of daily marijuana use and its potential links to substance use disorders, affecting nearly half of these daily users and their communities. The episode delves into whether marijuana is replacing alcohol or tobacco consumption and examines how high-potency cannabis, diverse consumption methods, and lower THC prices are influencing these trends. Dr. Calkins dispels the persistent myth that marijuana isn't addictive, backing his claims with solid scientific evidence. Tune in for an enlightening conversation that challenges conventional wisdom and offers deep insights into the evolving nature of marijuana consumption.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Enjoy this 10-minute highlight from Luke's marijuana legalization debate with top Colorado libertarian Jon Caldara, head of the Independence Institute. The full episode can be found on SAM's YouTube Channel. Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Navigating the intricate maze of advocacy and injustice requires both courage and tenacity, qualities that the former president of the Illinois State Conference of the NAACP has in abundance. Join us for this uplifting and exciting conversation on advocacy and making real change. Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

When Will Jones speaks, you can't help but listen. The Director of Community Engagement and Outreach at SAM brought his intense passion for marijuana policy to our conversation, enlightening us on the often overlooked complexities and challenges surrounding substance abuse in our society. His journey, deeply rooted in the experiences of his community and church, highlights the stark reality of alcohol and tobacco's impact, prompting us to consider if a third recreational substance is a burden we're prepared to shoulder. Our discussion navigates through the implications of the "Two is Enough" campaign and delves into Will's compelling reasons for opposing Initiative 71 in DC, offering a perspective that often goes unheard amidst the pro-legalization clamor.Our chat takes a turn into the murky waters of big tobacco, vaping, and their questionable affiliations with social justice. I bring to light the disturbing past of tobacco moguls who once denied nicotine's addictive qualities, tying it back to our eye-opening video on the Smart Approaches to Marijuana YouTube channel. Will and I dissect how these industries have co-opted social justice narratives, despite data that contradicts their claims of reducing arrests or incarceration rates for marginalized communities. As we unpack these complexities, Will invites our listeners to join the conversation on social media and online forums, challenging us to critically assess the data and ally ourselves with genuine social justice causes.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Kevin joins us to untangle the complex shifts in North American legislation. Our discussion kicks off with a deep dive into the Milgram's stunning hearing, a perhaps unexpected twist. Next we take you to the front lines of the drug decriminalization debate in British Columbia. Here, the government just announced the roll-back of its all-drug decriminalization policy amid a rising tide of public health emergencies and societal concerns. With Kevin's expert insight, we break down the political chess game influencing Canada's approach to drugs, spotlighting the importance of balancing criminal justice with public health. This is an unflinching exploration of the policies that shape our communities and the lives at stake in the throes of opioid crises and beyond.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

We sit down with Jordan, our head of federal affairs, to dissect the implications of marijuana potentially moving to Schedule III. This seismic shift has the industry abuzz, with financial windfalls and NASDAQ listings in sight for players like Curaleaf, but it's not all green pastures. Listen closely as we explore the critical social justice issues that could be overshadowed by the allure of tax deductions and the upcoming budget hearing with DEA Administrator Ann Milgram, where the conversation will undoubtedly continue.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

One of his best interviews, we're calling it the Encyclopedia Sabet-annica...Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Kevin Sabet joins the conversation, bringing a laser-sharp focus to the seismic shifts that may redefine the cannabis landscape. Prepare to arm yourself with knowledge as we dissect the implications of potentially reclassifying marijuana from a Schedule 1 to Schedule 3 substance, an issue that's got stakeholders from Wall Street to Main Street perched on the edge of their seats. As rumors of an imminent decision swirl, we cut through the haze to analyze what this monumental move would mean.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Discover the unsettling truth behind vaping addiction and its intrusion into youth culture as addiction psychologist Dr. Aaron Weiner joins us to unravel the threads of behavioral health entwined with corporate profit.  Dr. Weiner's expertise shines a harsh but necessary light on the over two million kids now embroiled in nicotine use, and the shadowy influence of THC on young adults. This isn't just a health crisis; it's a maze where capitalism meets drug markets, and our exploration is set to offer both clarity and a call to action.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Luke & Kevin discuss enforcement actions across cities like Vancouver and Denver, where the day's significance is being reshaped by a growing commercial presence and evolving regulatory responses. As we peel back the layers of this phenomenon, you'll gain a deeper understanding of the industry's consolidation, with a focus on Canadian corporations' acquisitions of local dispensaries. We also navigate the changing media narratives that now scrutinize marijuana's health implications, offering a fresh perspective on the conversation surrounding cannabis and its impact on youth.Unravel with us the tangled web of marijuana legalization as we delve into the recent federal seizures in New Mexico, an issue that highlights the friction between state legislation and federal authority. Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Discover the dark underbelly of the U.S. marijuana market as expert Jordan Davidson joins us to expose the role of Chinese criminal syndicates in cannabis trade and the complex implications for U.S. drug policy. We also discuss the Safe Banking Act and its unintended consequences, offering a financial lifeline to those laundering profits from deadly substances like fentanyl. Also, the VA's recent findings on marijuana's ineffectiveness in treating PTSD, challenging the hype often seen on social media with cold, hard science. This episode strips back the curtain on the intricate and hidden connection between marijuana businesses and illicit drug trafficking.This conversation also steers us into the haze of 420 celebrations and the widespread normalization of cannabis use. As we witness the cultural shift around this high-potency plant, we question the silent messages sent to our youth and consider the plight of individuals struggling with cannabis use disorders amidst aggressive marijuana marketing. We explore Colorado's challenges in keeping these public festivities adult-exclusive and scrutinize the role of public officials like Governor Jared Polis in stoking the industry's flames. Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Critical examination of marijuana legalization with Dr. Eric Voth, a leading voice in internal medicine, pain management, and addiction medicine, and the president of the International Academy on the Science and Impact of Cannabis. Dr. Voth explains the maze of medical and scientific considerations that accompany the shifting sands of "medical marijuana" policy. As we navigate the complexities of public health and safety implications, you'll gain a deeper understanding of the stark realities and challenges the medical community faces in states like Kansas, where the battle against legalization is fierce. This episode promises to arm you with knowledge and perspective on an issue that is as controversial as it is current.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Luke interviews Dr. Gary Kirkilas, as the Phoenix, AZ pediatrician takes us behind the scenes of his mobile medical unit, revealing the startling transformation in how today's youth perceive and use marijuana. Dr. Kirkilas shares eye-opening anecdotes from at-risk communities, showing a trend where teens now view cannabis as a go-to remedy for common ailments such as ADHD and anxiety. This episode digs into the troubling normalization of marijuana and the resulting increase in cannabis use disorder and hyperemesis in children—conditions that are alarmingly under-recognized. Hear the inside story of how disparate groups, including medical professionals, substance abuse advocates, and even billboard companies, came together to shape a bill that addresses the void left by the 2020 voter initiative. From the consensus on banning cartoon imagery to the establishment of billboard distance regulations, this episode illuminates the triumphs and challenges in navigating public health advocacy in a state with commercial marijuana.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Luke goes over the giant Ed Board pieces over the weekend, key statistics driving this analysis, and much more. Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Luke & Kevin interview Dr. Ken Finn from Colorado Springs who just wrapped up his RX Summit panel with CDC and NIH on marijuana, then they discuss the news of the week including Hawaii's big win and Pennsylvania's latest marijuana developments.  Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Luke discusses the stories driving the week, including Distracted Driving Month and the FDA's announcements about "Gas Station Heroin" and just what that is!Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Luke is joined by Kevin Sabet and Jordan Davidson from SAM to discuss the new Romney-led Senate letter on rescheduling and treaty obligations, as well as how international treaties interact with the current DEA review.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Luke discusses the latest stories outlining China's growing involvement in state-legal marijuana markets, including rising money laundering concerns. He then interviews Jordan Davidson, SAM's head of Federal Affairs, for an update on multiple marijuana policy developments in DC.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Luke & Kevin interview Europe drug policy expert and head of EURAD, Stig Erik, who gives insight on Germany's marijuana legalization efforts, broader drug policy in Europe, and America's influence in his region.  Follow EURAD's efforts on Twitter: @EURADnews Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Kevin delivers a thunderous 3 minutes of remarks on behalf of SAM & FDPS to the UN's 67th CND, before all the member states to tremendous applause. Listen as he reminds member states of their treaty obligations to reject drug legalization & outlines the failures of extreme policies in Oregon, Canada, and more.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Luke & Kevin go over the drug policy news and events driving the discussion this week, as well as give an update on SAM & FDPS' Europe and UN events. Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Today's episode covers the new JAMA study finding a substantial number of American 12th graders are using Delta-8 THC, what Delta-8 is, and what needs to be done about it. Chris Tremoglie from the Washington Examiner joins us to talk about his latest marijuana editorial and why he got involved in the issue.Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

-Biden SOTU remarks on marijuana policy-Kevin's WSJ oped on Oregon rolling back Measure 110-Ohio is about to spend $8 mil for new police dogs as a result of legalization of marijuana-Interview with the illustrious Tom Wolf about Oregon's seismic waves on drug policy reaching SF, California, and his work to advance the ball for recovery (Follow him on X at @twolfrecovery)Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Today's episode is a break from the regular news updates to dive deep into the UN's international drug work, primarily through the United Nations Office on Drugs and Crime. Luke and Kevin will be at their upcoming annual Commission on Narcotic Drugs and discuss their events, involvement, and how other NGO's can get involved, too.  Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Discussion of the news driving the week in drug policy, from Oregon's repeal of Measure 110 to marijuana's impact on the environment. Luke interviews SAM Policy Associate Connor Kubeisy for key insights in his recent The Drug Review piece on Oregon's drug policy data outcomes. Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam

Discussion of latest stories driving the TDR Newsletter, Senator Mitch McConnell's announcement and implications, and the podcast's first interview - with Crissy Groenwegen, SAM's Director of the Parent Action Network (PAN). https://parentaction.network/Follow the work of SAM and FDPS below:https://learnaboutsam.org/https://gooddrugpolicy.org/https://thedrugreport.org/On X: https://twitter.com/learnaboutsamhttps://twitter.com/GoodDrugPolicyhttps://twitter.com/KevinSabethttps://twitter.com/LukeNiforatosOn Facebook: https://www.facebook.com/learnaboutsam